Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05029531 | Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) | recruiting | Phase 3 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 |
| clinicaltrials |
| NCT06418776 | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | recruiting | Phase 3 | 198 | National Research Center for Hematology, RussiaNETWORK | 1 | May 17, 2024 | clinicaltrials |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | recruiting | Phase 3 | 146 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06179732 | Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities | completed | Phase 3 | 2,400 | The Mentor InitiativeOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT01751997 | Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors | completed | Phase 2 / Phase 3 | 116 | Byung-Sik ChoOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V) | terminated | Phase 2 / Phase 3 | 277 | TG Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia(AML) | terminated | Phase 3 | 9 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06345365 | MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 154 | Zhongnan HospitalOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03959241 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)(1703/1801) | completed | Phase 3 | 431 | Medical College of WisconsinOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06205290 | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 11 | Apr 2, 2024 | clinicaltrials |
| NCT00381680 | Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | completed | Phase 3 | 275 | Children's Oncology GroupNETWORK | 4 | Mar 26, 2024 | clinicaltrials |
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02013648 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | completed | Phase 3 | 204 | University of UlmOTHER | 2 | Feb 23, 2024 | clinicaltrials |
| NCT01802814 | International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 | completed | Phase 3 | 700 | Charite University, Berlin, GermanyOTHER | 17 | Feb 9, 2024 | clinicaltrials |
| NCT02473146 | Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4(ALFA1401) | completed | Phase 2 / Phase 3 | 225 | Versailles HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT01497002 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a(AML2004) | completed | Phase 3 | 1,222 | University of LeipzigOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT00630565 | Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 / Phase 3 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT02461537 | Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML(ETAL3-ASAP) | completed | Phase 3 | 281 | DKMS gemeinnützige GmbHOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06211452 | Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 3 | 258 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | completed | Phase 3 | 556 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Dec 11, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04145531 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | completed | Phase 2 / Phase 3 | 229 | Jazz PharmaceuticalsINDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT05328258 | Use of GnRHa During Chemotherapy for Fertility Protection(ProFertil) | recruiting | Phase 3 | 500 | Kenny Rodriguez-WallbergOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02005471 | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)(MURANO) | completed | Phase 3 | 389 | Hoffmann-La RocheINDUSTRY | 20 | Oct 17, 2023 | clinicaltrials |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS(THRIVE) | terminated | Phase 2 / Phase 3 | 1 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | active not recruiting | Phase 3 | 56 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02004522 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | completed | Phase 3 | 319 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | completed | Phase 3 | 99 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02140242 | Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML(DaunoDouble) | completed | Phase 3 | 721 | Technische Universität DresdenOTHER | 2 | Sep 15, 2023 | clinicaltrials |
| NCT01951885 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | completed | Phase 3 | 101 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 511 | Novartis PharmaceuticalsINDUSTRY | 20 | Aug 21, 2023 | clinicaltrials |
| NCT00488605 | H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis | withdrawn | Phase 3 | 0 | University of New MexicoOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05313958 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children(SCCLG-M5) | unknown | Phase 2 / Phase 3 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia(SIERRA) | active not recruiting | Phase 3 | 153 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 19, 2023 | clinicaltrials |
| NCT00046930 | Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | completed | Phase 3 | 449 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jul 5, 2023 | clinicaltrials |
| NCT03719534 | Haplo HCT vs Haplo-cord HCT for Patients With AML | completed | Phase 3 | 134 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00002868 | Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | completed | Phase 3 | 744 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT00002514 | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | completed | Phase 3 | 1,929 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00003764 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 280 | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 18, 2023 | clinicaltrials |
| NCT00049517 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | completed | Phase 3 | 657 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT05188326 | Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients | completed | Phase 3 | 54 | Associazione Qol-oneOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05264883 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | unknown | Phase 3 | 170 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
| NCT00413439 | Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy | completed | Phase 2 / Phase 3 | 18 | Basilea PharmaceuticaINDUSTRY | 1 | May 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 28, 2024source: clinicaltrials